FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2143180816> ?p ?o ?g. }

• W2143180816 endingPage "792.e9" @default.
• W2143180816 startingPage "784" @default.
• W2143180816 abstract "Background & AimsConcomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin increases the risk of upper gastrointestinal bleeding (UGIB). Guidelines suggest avoiding certain drug combinations, yet little is known about the magnitude of their interactions. We estimated the risk of UGIB during concomitant use of nonselective (ns)NSAIDs, cyclooxygenase -2 selective inhibitors (COX-2 inhibitors), and low-dose aspirin with other drugs.MethodsWe performed a case series analysis of data from 114,835 patients with UGIB (930,888 person-years of follow-up) identified from 7 population-based health care databases (approximately 20 million subjects). Each patient served as his or her own control. Drug exposure was determined based on prescriptions of nsNSAIDs, COX-2 inhibitors, or low-dose aspirin, alone and in combination with other drugs that affect the risk of UGIB. We measured relative risk (incidence rate ratio [IRR] during drug exposure vs nonexposure) and excess risk due to concomitant drug exposure (relative excess risk due to interaction [RERI]).ResultsMonotherapy with nsNSAIDs increased the risk of diagnosis of UGIB (IRR, 4.3) to a greater extent than monotherapy with COX-2 inhibitors (IRR, 2.9) or low-dose aspirin (IRR, 3.1). Combination therapy generally increased the risk of UGIB; concomitant nsNSAID and corticosteroid therapies increased the IRR to the greatest extent (12.8) and also produced the greatest excess risk (RERI, 5.5). Concomitant use of nsNSAIDs and aldosterone antagonists produced an IRR for UGIB of 11.0 (RERI, 4.5). Excess risk from concomitant use of nsNSAIDs with selective serotonin reuptake inhibitors (SSRIs) was 1.6, whereas that from use of COX-2 inhibitors with SSRIs was 1.9 and that for use of low-dose aspirin with SSRIs was 0.5. Excess risk of concomitant use of nsNSAIDs with anticoagulants was 2.4, of COX-2 inhibitors with anticoagulants was 0.1, and of low-dose aspirin with anticoagulants was 1.9.ConclusionsBased on a case series analysis, concomitant use of nsNSAIDs, COX-2 inhibitors, or low-dose aspirin with SSRIs significantly increases the risk of UGIB. Concomitant use of nsNSAIDs or low-dose aspirin, but not COX-2 inhibitors, with corticosteroids, aldosterone antagonists, or anticoagulants produces significant excess risk of UGIB. Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin increases the risk of upper gastrointestinal bleeding (UGIB). Guidelines suggest avoiding certain drug combinations, yet little is known about the magnitude of their interactions. We estimated the risk of UGIB during concomitant use of nonselective (ns)NSAIDs, cyclooxygenase -2 selective inhibitors (COX-2 inhibitors), and low-dose aspirin with other drugs. We performed a case series analysis of data from 114,835 patients with UGIB (930,888 person-years of follow-up) identified from 7 population-based health care databases (approximately 20 million subjects). Each patient served as his or her own control. Drug exposure was determined based on prescriptions of nsNSAIDs, COX-2 inhibitors, or low-dose aspirin, alone and in combination with other drugs that affect the risk of UGIB. We measured relative risk (incidence rate ratio [IRR] during drug exposure vs nonexposure) and excess risk due to concomitant drug exposure (relative excess risk due to interaction [RERI]). Monotherapy with nsNSAIDs increased the risk of diagnosis of UGIB (IRR, 4.3) to a greater extent than monotherapy with COX-2 inhibitors (IRR, 2.9) or low-dose aspirin (IRR, 3.1). Combination therapy generally increased the risk of UGIB; concomitant nsNSAID and corticosteroid therapies increased the IRR to the greatest extent (12.8) and also produced the greatest excess risk (RERI, 5.5). Concomitant use of nsNSAIDs and aldosterone antagonists produced an IRR for UGIB of 11.0 (RERI, 4.5). Excess risk from concomitant use of nsNSAIDs with selective serotonin reuptake inhibitors (SSRIs) was 1.6, whereas that from use of COX-2 inhibitors with SSRIs was 1.9 and that for use of low-dose aspirin with SSRIs was 0.5. Excess risk of concomitant use of nsNSAIDs with anticoagulants was 2.4, of COX-2 inhibitors with anticoagulants was 0.1, and of low-dose aspirin with anticoagulants was 1.9. Based on a case series analysis, concomitant use of nsNSAIDs, COX-2 inhibitors, or low-dose aspirin with SSRIs significantly increases the risk of UGIB. Concomitant use of nsNSAIDs or low-dose aspirin, but not COX-2 inhibitors, with corticosteroids, aldosterone antagonists, or anticoagulants produces significant excess risk of UGIB." @default.
• W2143180816 created "2016-06-24" @default.
• W2143180816 creator A5016458469 @default.
• W2143180816 creator A5023215576 @default.
• W2143180816 creator A5031396246 @default.
• W2143180816 creator A5040113589 @default.
• W2143180816 creator A5043485479 @default.
• W2143180816 creator A5052413250 @default.
• W2143180816 creator A5055137783 @default.
• W2143180816 creator A5061279178 @default.
• W2143180816 creator A5070504206 @default.
• W2143180816 creator A5071030647 @default.
• W2143180816 creator A5077586396 @default.
• W2143180816 creator A5081503066 @default.
• W2143180816 creator A5082236476 @default.
• W2143180816 creator A5084301044 @default.
• W2143180816 creator A5087002297 @default.
• W2143180816 date "2014-10-01" @default.
• W2143180816 modified "2023-10-18" @default.
• W2143180816 title "Risk of Upper Gastrointestinal Bleeding From Different Drug Combinations" @default.
• W2143180816 cites W1753403480 @default.
• W2143180816 cites W1903416688 @default.
• W2143180816 cites W1976594978 @default.
• W2143180816 cites W1984605918 @default.
• W2143180816 cites W1985435023 @default.
• W2143180816 cites W1986304743 @default.
• W2143180816 cites W1991114001 @default.
• W2143180816 cites W1992141244 @default.
• W2143180816 cites W1994010716 @default.
• W2143180816 cites W2005769804 @default.
• W2143180816 cites W2024938998 @default.
• W2143180816 cites W2035138894 @default.
• W2143180816 cites W2039149640 @default.
• W2143180816 cites W2040614525 @default.
• W2143180816 cites W2041327755 @default.
• W2143180816 cites W2043177024 @default.
• W2143180816 cites W2043396343 @default.
• W2143180816 cites W2044214724 @default.
• W2143180816 cites W2050145647 @default.
• W2143180816 cites W2057800760 @default.
• W2143180816 cites W2058837954 @default.
• W2143180816 cites W2066629760 @default.
• W2143180816 cites W2069643552 @default.
• W2143180816 cites W2071543617 @default.
• W2143180816 cites W2083310443 @default.
• W2143180816 cites W2092902579 @default.
• W2143180816 cites W2094320722 @default.
• W2143180816 cites W2096219546 @default.
• W2143180816 cites W2118910625 @default.
• W2143180816 cites W2120642548 @default.
• W2143180816 cites W2137903085 @default.
• W2143180816 cites W2148303708 @default.
• W2143180816 cites W2156662512 @default.
• W2143180816 cites W2163756514 @default.
• W2143180816 cites W2166587212 @default.
• W2143180816 cites W2167505959 @default.
• W2143180816 cites W2169041339 @default.
• W2143180816 cites W2171508983 @default.
• W2143180816 cites W2330496155 @default.
• W2143180816 cites W2331085743 @default.
• W2143180816 doi "https://doi.org/10.1053/j.gastro.2014.06.007" @default.
• W2143180816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24937265" @default.
• W2143180816 hasPublicationYear "2014" @default.
• W2143180816 type Work @default.
• W2143180816 sameAs 2143180816 @default.
• W2143180816 citedByCount "118" @default.
• W2143180816 countsByYear W21431808162014 @default.
• W2143180816 countsByYear W21431808162015 @default.
• W2143180816 countsByYear W21431808162016 @default.
• W2143180816 countsByYear W21431808162017 @default.
• W2143180816 countsByYear W21431808162018 @default.
• W2143180816 countsByYear W21431808162019 @default.
• W2143180816 countsByYear W21431808162020 @default.
• W2143180816 countsByYear W21431808162021 @default.
• W2143180816 countsByYear W21431808162022 @default.
• W2143180816 countsByYear W21431808162023 @default.
• W2143180816 crossrefType "journal-article" @default.
• W2143180816 hasAuthorship W2143180816A5016458469 @default.
• W2143180816 hasAuthorship W2143180816A5023215576 @default.
• W2143180816 hasAuthorship W2143180816A5031396246 @default.
• W2143180816 hasAuthorship W2143180816A5040113589 @default.
• W2143180816 hasAuthorship W2143180816A5043485479 @default.
• W2143180816 hasAuthorship W2143180816A5052413250 @default.
• W2143180816 hasAuthorship W2143180816A5055137783 @default.
• W2143180816 hasAuthorship W2143180816A5061279178 @default.
• W2143180816 hasAuthorship W2143180816A5070504206 @default.
• W2143180816 hasAuthorship W2143180816A5071030647 @default.
• W2143180816 hasAuthorship W2143180816A5077586396 @default.
• W2143180816 hasAuthorship W2143180816A5081503066 @default.
• W2143180816 hasAuthorship W2143180816A5082236476 @default.
• W2143180816 hasAuthorship W2143180816A5084301044 @default.
• W2143180816 hasAuthorship W2143180816A5087002297 @default.
• W2143180816 hasBestOaLocation W21431808161 @default.
• W2143180816 hasConcept C120195587 @default.
• W2143180816 hasConcept C120665830 @default.
• W2143180816 hasConcept C121332964 @default.
• W2143180816 hasConcept C126322002 @default.
• W2143180816 hasConcept C167704817 @default.

• next